Ovarian Cancer Research and Clinical Trials

Our epidemiologists are exploring factors that influence a woman’s risk for ovarian cancer and how that risk could be lowered. For example, they are investigating whether night-shift work is linked with ovarian cancer, as it is with breast cancer. They are also exploring whether lifestyle factors and medications may help reduce risk of the disease. And they are working to make sure all people get high-quality cancer care regardless of age, income, race or other characteristics.

Most ovarian cancers are found at an advanced stage. So, much of our ovarian cancer research is aimed at improving early detection. For example, our researchers created an effective symptom-screening tool to aid in diagnosis. We’re also seeking out new biomarkers (molecules that indicate cancer is present) and studying how to better use imaging to improve ovarian cancer detection.

Not all patients respond to ovarian cancer chemotherapies. Our investigators are using proteogenomics (genetic and protein analysis) to predict which patients will respond — and which won’t, so they can avoid getting these treatments. This new approach may also help to identify new targets that can be used against ovarian cancer. We’re also studying immunotherapies, which harness the immune system. 

Many ovarian cancers are driven by inherited mutations in the BRCA1 or BRCA2 genes. Our researchers continue to look for new genetic drivers of this disease. They are also studying how the body’s immune system responds to ovarian cancer cells and the signaling pathways the cancer cells use.